Search
ARS Pharmaceuticals Inc
SPRYAdd to Watchlist
4.150USD
-0.030-0.72%
Close 09-24 16:00（ET）
412.10MMarket Cap
LossP/E TTM
ARS Pharmaceuticals Inc (SPRY) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to ARS Pharmaceuticals Inc in the past month.
Strong Buy
3 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
26.500USD+533.97%
SPRY Analyst Recommendation Trends
In the current month, SPRY has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SPRY average Analyst price target in the last month is 26.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
4
4
4
4
1
1
1
2
3
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
5
7
6
6
6
SPRY Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, SPRY EPS is projected to reach -0.313 in FY2026Q3, following reported EPS of -0.628 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.44
-0.53
-0.49
-0.31
-0.30
Actual
-0.42
-0.61
-0.63
--
--
Surprise
+5.52%
-16.17%
-27.45%
--
--
FAQs
What is ARS Pharmaceuticals Inc's expected revenue for the next quarter?
ARS Pharmaceuticals Inc's expected revenue is 42.84M.
What is ARS Pharmaceuticals Inc's price target?
Analysts forecast that ARS Pharmaceuticals Inc's price target is USD 26.50, with the highest forecast at USD 33.00 and the lowest forecast at USD 15.00.
How have ARS Pharmaceuticals IncSPRY's recent earnings per share performed?
The market expectation was USD -0.63, while ARS Pharmaceuticals IncSPRY's earnings per share (EPS) for the previous quarter was USD -0.61. EPS for the next quarter is expected at USD -0.31.
What is the analyst rating for ARS Pharmaceuticals Inc?
Based on the ratings of ARS Pharmaceuticals Inc's stock from 4 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.